This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research into the mechanisms underlying autosomal dominant polycystic kidney disease (ADPKD). The $1,472,604 award to the Children's Hospital Medical Center in Cincinnati, OH aims to elucidate how a second somatic mutation in renal cells affects their behavior and the progression of cystic disease in...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $135,582 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the University of Oklahoma Health Sciences Center to construct a single-cell atlas of mouse and human cells in autosomal dominant polycystic kidney disease (ADPKD). The project aims to understand how molecular and cellular pathways found in ADPKD patients correlate to mouse models, and to identify inter-...
This federal Project Grant award of $640,001.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, which runs from January 1, 2025 to November 30, 2028, supports research conducted by Yale University to explore the mechanisms by which the protein polycystin-1 (PC1) and its C-terminal fragments affect mitochondrial function and cellular energy...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate the role of the CDKN1A (P21) protein in regulating cyst growth and development in polycystic kidney disease (PKD). The $587,212 award to the University of Alabama at Birmingham will fund a 4-year research project to determine how abnormal P21 expression contributes to cyst initiation and expansion in...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $223,918 to the University of Oklahoma Health Sciences Center to study "Targeting Kidney Resident Macrophage Niche Filling to Slow Cystic Kidney Disease". The project aims to understand the mechanism of kidney resident macrophage (KRM) niche filling after temporary depletion and identify factors like...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $225,304 to Northwestern University for research on polycystin proteins and their role in autosomal dominant polycystic kidney disease (ADPKD). The primary goals of this project are to: 1) Characterize the functional consequences of ADPKD disease-causing variants in the PKD2 gene using...
The University of Pittsburgh received a $198,750 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to develop a rapid, quantitative platform using yeast to classify how approximately 70 identified mutations in the polycystin-1 (PC1) protein disrupt channel activity with PC2. This research aims to provide new reagents and assays to the scientific and PKD (polycystic kidney disease) community to study the molecular defects of PC1 mutants. The...
This $142,902 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to uncover the mechanism by which the regulatory GTPase ARL13B drives polycystic kidney disease (PKD) pathogenesis. The research, led by Dr. Van Sciver at Emory University, will biochemically and genetically dissect ARL13B's interaction with three effector proteins - CDK1, ARL3,...
The Project Grant award of $666,890, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program), supports a parallel-group randomized controlled trial to evaluate the efficacy of pioglitazone versus empagliflozin for treating diabetes mellitus associated with chronic pancreatitis and recurrent acute pancreatitis (CP-DM). The study, titled "PEP-DM Trial," will be conducted at the...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $200,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Washington University in St. Louis. The goal of this R56 award is to delineate the molecular mechanism regulating autophagy in Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) caused by UMOD mutations. The university will use CRISPR/Cas9 technology to generate the first...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $2,063,777 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the University of Colorado-Denver to conduct a 24-month, randomized, placebo-controlled, double-blind clinical trial evaluating the efficacy, safety, and mechanisms of a glucagon-like peptide-1 receptor agonist (GLP-1RA) in slowing kidney disease progression in 126 adults with autosomal dominant polycystic kidney disease (ADPKD) and overweight/obesity. The study aims to determine the effect of the GLP-1RA on kidney growth, as well as changes in body weight, adipose volume and function, insulin resistance, kidney oxidative metabolism, and inflammation. A sub-award of an unspecified amount was provided to the University of Washington to support this research project.